Preliminary results of clinical activity indicated promising anti-tumor efficacy in patients with CEA+ solid tumors (mostly colorectal cancer) when cibisatamab was combined with the anti-PD-L1 antibody atezolizumab (55). The gene discussed is CEACAM5; the disease is colorectal cancer.